GlassScriptPhysician profile
Keith D Lobel
NPI 1407864671
$3,206.73
in general payments reported to CMS, 2019-2025
39 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $268 · 2021: $45.08 · 2022: $784 · 2023: $739 · 2024: $419 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $441.10 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $280.97 | 2019-2025 | |
| Novo Nordisk INC | $274.11 | 2019-2025 | Wegovy, Ozempic |
| Abbott Laboratories | $228.01 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $227.81 | 2019-2024 | Breztri, Farxiga |
| Dexcom, INC. | $207.86 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $176.12 | 2019-2024 | Zepbound, Jardiance, Emgality |
| Pfizer INC. | $148.83 | 2019-2025 | |
| Amgen INC. | $136.75 | 2019-2024 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $122.08 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $105.58 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $82.41 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.78 | 2020-2022 | |
| Daiichi Sankyo INC. | $63.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $62.03 | 2022-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.